Taux de reprise et de retraitement avec l'Ixekizumab après l'arrêt du traitement chez les patients atteints de spondylarthrite axiale : Résultats à la semaine 104 d'une étude de retrait randomisée contrôlée par placebo
Ann Rheum Dis. 2022 doi: 10.1136/ard-2022-222731
The present analysis demonstrated that patients continuously treated with IXE were less likely to experience flare compared with patients receiving placebo. The aim of this study was to evaluate the recapture of response with open-label IXE retreatment at week 104 in patients with axSpA who flared after withdrawal of IXE therapy.
The vast majority of patients withdrawn from IXE to placebo recaptured at least LDA and over half of those patients met the criteria for ID with IXE retreatment. These data may provide support to patients who require interruption in active therapy.
Keywords:
